Paradigm Biopharmaceuticals Ltd (ASX:PAR) Announces Phase 3 Trial Launch and Financial Update
Paradigm Biopharmaceuticals (ASX:PAR) announces the launch of its Phase 3 trial for knee osteoarthritis and the receipt of a $6.3 million R&D tax refund.
Paradigm Biopharmaceuticals (ASX:PAR) announces the launch of its Phase 3 trial for knee osteoarthritis and the receipt of a $6.3 million R&D tax refund.
InteliCare Holdings Ltd (ASX:ICR) partners with mecwacare to trial its AI-driven platform at Trescowthick Centre, enhancing aged care services in Victoria.
4DMedical Limited (ASX:4DX) achieves 103% YTD revenue growth and secures key strategic partnerships in Q3 FY2025.
Australian Rare Earths Limited (ASX:AR3) extends uranium mineralisation at Overland Project, supporting calcrete-hosted model with assay results expected soon.
Zelira Therapeutics (ASX:ZLD) enhances financial flexibility with a $1.15M R&D refund and a $1M ATM facility to support ongoing developments.
Rimfire Pacific Mining (ASX:RIM) announces successful Q1 scandium drilling at Murga and Currajong, and raises $3.65M in funding.
Odyssey Gold Limited (ASX:ODY) has launched a Technical Study to evaluate mining and processing options for its Tuckanarra Gold Project.
Immutep Limited (ASX:IMM) announces significant clinical trial milestones and maintains a robust cash position in its Q3 FY25 report.
Health and Plant Protein Group Limited (ASX:HPP) releases FY25 Q3 report, highlighting cash flow and ongoing IRS repayment efforts.
BrainChip Holdings Ltd (ASX:BRN) releases Q1 2025 report, highlighting key partnerships and a solid financial position.